Cyclosporin A versus Cyclophosphamide in the Treatment of Nephrotic Syndrome in Children
Authors:
Ľ. Podracká 1; A. Böör 2; M. Šašinka 1
Authors‘ workplace:
Klinika detí a dorastu LF UPJŠ, Košice, Slovenská republika
1; Ústav patologickej anatómie LF UPJŠ, Košice, Slovenská republika
2
Published in:
Čas. Lék. čes. 2008; 147: 38-43
Category:
Original Article
Overview
Background.
The majority of cases of nephrotic syndrome in children is corticosensitive, however in some individuals aggressive cytotoxic therapy is necessary. Cyclosporin A and cyclophosphamide are widely used; however their relative effectiveness in maintaining remission of childhood nephrotic syndrome remains controversial.
Methods and Results.
Effectiveness of long-term cytotoxic therapy (mean follow-up 7.4 years) in 63 children (mean age 6.19 ± 4.30 years) with nephrotic syndrome was retrospectively analyzed; 14 patients suffered from corticosensitive, 33 from corticodependent and 16 from corticoresistant nephrotic syndrome. Corticotherapy alone was used in 15 patients (23.8%), cyclophosphamide was added in 27 (42.9%) and cyclosporin A in 38 cases (60.3%), while 17 patients (27%) were on both immunosuppressive agents. 84% children relapsed within 24 months after cessation of cyclosporin A. In 8 corticoresistant nephrotic syndrome patients (61.5 %) from 13 children treated with cyclosporin A no remission occurred, in 5 children (38.5 %) was remission obtained within 10 weeks, however in 4 of them relapsed disease during cyclosporin A therapy. 19 (70.4%) of 27 patients on cyclophosphamide therapy were in remission, in 8 of them (42.1%) even 2 years after cyclophosphamide therapy.
Conclusions.
Cyclophosphamide therapy of childhood nephrotic syndrome is more effective in maintaining long-term remission than cyclosporin A treatment.
Key words:
childhood idiopathic nephrotic syndrome, corticoresistant nephrotic syndrome, cyclosporin A, cyclophosphamide.
Sources
1. Eddy, A. A., Symons, J. M: Nephrotic syndrome in childhood. Lancet, 2003, 362, s. 629–639.
2. Collaborative Study Group of Sandimmune in nephrotic syndrome: Safety and tolerability of cyclosporin A (Sandimmune) in idiopathic nephrotic syndrome. Clin. Nephrol., 1991, 35, s. 48–60.
3. Hladík, M.: Léčba nefrotického syndromu cyklosporinem A u dětí. In: Buchanec, J. et al.: Vybrané kapitoly z pediatrie V., JLF UK Martin, 1998, s. 50–52.
4. Tejani, A., Butt, K., Trachtman, H. et al.: Cyclosporin–induced remission of relapsing nephrotic syndrome in children. J. Pediatr., 1987, 111, s. 1056–1062.
5. Ponticelli, C., Edefonti, A., Rizzoni, G. et al.: Cyclosporin versus cyclophosphamide for patients with steroid–dependent and frequently relapsing idiopathic nephrotic syndrome: A multicentre randomized controlled trial. Nephrol. Dial. Transplant., 1993, 8, s. 1326–1332.
6. Tohjoh, S., Narita, M., Koyama, T.: Clinical evaluation of cyclosporin in the treatment of nephrotic syndrome: Multicenter double blind study. Jin To Tohseki, 1994, 37, s. 565–608.
7. Kitano, Y., Yoshikawa, N., Tanaka, R. et al.: Cyclosporin treatment in children with steroid-dependent nephrotic syndrome. Pediatr. Nephrol., 1990, 4, s. 474–477.
8. Meyrier, A.: Use of cyclosporin in the treatment of idiopathic nephrotic syndrome in adults. Contrib. Nephrol., 1995, 114, s. 28–48.
9. Feutren, G., Mihatsch, M.: Risk factors for cyclosporine–induced nephrotoxicity in patients with autoimmune diseases. N. Engl. J. Med., 1992, 326, s. 1654–1660.
10. Myers, B. D.: Cyclosporin nephrotoxicity. Kidney Int., 1986, 30, s. 964–974.
11. International Study of Kidney Disease in Children (ISKDC): Primary nephrotic syndrome in children: Clinical significance of histopathologic variants of minimal change and of diffuse mesangial hypercellularity. Kidney Int., 1981, 20, s. 765–771.
12. Ronald, J. H., Ronald, J. P., Dawn, M. et al.: Evaluation and Management of Proteinuria and Nephrotic Syndrome in Children: Recommendations From a Pediatric Nephrology Panel Established at the National Kidney Foundation Conference on Proteinuria, Albuminuria, Risk, Assessment, Detection, and Elimination (PARADE). Pediatrics, 2000, 105, s. 1242–1251.
13. Cameron, J. S., Chantler, C., Ogg, C. S. et al.: Long-term stability of remission in nephrotic syndrome after treatment with cyclophosphamide. Br. Med. J., 1974, 4, s. 7–11.
14. Niaudet, P., Broyer, M., Habib, R.: Treatment of idiopathic nephrotic syndrome with cyclosporin A in children. Clin. Nephrol., 1991, 35, s. 31–36.
15. Tanaka, R., Yoshikawa, N., Kitano, Y. et al.: Long-term cyclosporin treatment in children with steroid-dependent nephrotic syndrome. Pediatr. Nephrol., 1993, 7, s. 249–252.
16. Niaudet, P.: Comparison of cyclosporine and chlorambucil in the treatment of idiopathic nephrotic syndrome: A multicenter randomized controlled trial. The French Society of Pediatric Nephrology. Pediatr. Nephrol., 1992, 6, s. 1–3.
17. Satoshi, H., Tsukasa, T., Mitsuru, O. et al.: Follow-Up Study of Children With Nephrotic Syndrome Treated With a Long-Term Moderate Dose of Cyclosporine. Am. J. Kidney Dis., 1998, 31, s. 932–939.
18. Filler, G.: Treatment of nephrotic syndrome in children and controlled trials. Nephrol. Dial. Transplant., 2003, 18, 6, s. 75–78.
19. Tarshih, P., Tobin, J. N., Bernstein, J. et al.: Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis. Pediatr. Nephrol., 1996, 10, s. 590–593.
20. Geary, D. F., Farine, M., Thorner, P. et al.: Response to cyclophosphamide in steroid resistant focal segmental glomerulosclerosis. Clin. Nephrol., 1984, 22, s. 109.
21. Hladík, M.: Nefrotický syndrom u dětí. In: Buchanec, J. et al.: Vybrané kapitoly z pediatrie V., JLF UK Martin, 1999, s. 68–70.
22. Niaudet, P., Habib, R.: Cyclosporine in the treatment of idiopathic nephrosis. J. Am. Soc. Nephrol., 1994, 5, s. 1049–1056.
23. Lieberman, K. V., Tejani, A.: A randomized double–blind placebo–controlled trial of cyclosporine in steroid resistant idiopathic focal segmental glomerulosclerosis in children. J. Am. Soc. Nephrol., 1996, 7, s. 56–63.
24. Durkan, A. M., Hodson, E. M., Willis, N. S. et al.: Immunosuppressive agents in childhood nephrotic syndrome: A meta-analysis of randomized controlled trials. Kidney Int., 2001, 59, s. 1919–1927.
25. Pena, A., Bravo, J., Melgosa,M. et al.: Steroid-resistant nephrotic syndrome: long- term evolution after sequential therapy. Pediatr. Nephrol., 2007, 22, s. 1875–1880.
26. El-Husseini, A., El-Basuony, F., Mahmoud, I. et al.: Long-term effects of cyclosporine in children with idiopathic nephrotic syndrome: a single-centre experience. Nephrology Dialysis Transplantation, 2005, 20, s. 2433–2438.
27. Kyrieleis, H. A., Levtchenko, E. N., Wetzels, J. F.: Long-term outcome after cyclophosphamide treatment in children with steroid-dependent and frequently relapsing minimal change nephrotic syndrome. Am. J. Kidney Dis., 2007, 49, s. 592–597.
28. Reusz, G., Szabo, A., Telete, A.: Nephrotic syndrome in childhood. Orv Hetil, 2006, 147, s. 2251–2260.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain managementArticle was published in
Journal of Czech Physicians
Most read in this issue
- Essential Hypertension – Syndrome, or Compensatory Mechanism
- Preoperative Preparation and Examinations Before Scheduled Cardiosurgical Intervention
- Psychomotor Speed and Speed of Searching in Semantic Memory
- Clinical Utility of Bone Markers in the Evaluation and Follow-up in Patients with Neoplastic Bone Diseases